Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) FCF Margin (2016 - 2020)

KalVista Pharmaceuticals' FCF Margin history spans 7 years, with the latest figure at 330.18% for Q2 2020.

  • For Q2 2020, FCF Margin rose 3845.0% year-over-year to 330.18%; the TTM value through Jan 2021 reached 424.58%, down 5827.0%, while the annual FY2025 figure was 2651.72%, 283098.0% up from the prior year.
  • FCF Margin for Q2 2020 was 330.18% at KalVista Pharmaceuticals, up from 831.26% in the prior quarter.
  • Across five years, FCF Margin topped out at 1202.83% in Q1 2018 and bottomed at 4747.92% in Q3 2017.
  • The 5-year median for FCF Margin is 368.63% (2019), against an average of 1027.34%.
  • The largest annual shift saw FCF Margin crashed -416361bps in 2017 before it soared 573791bps in 2018.
  • A 5-year view of FCF Margin shows it stood at 2134.01% in 2016, then surged by 70bps to 648.62% in 2017, then soared by 75bps to 161.07% in 2018, then dropped by -26bps to 202.24% in 2019, then crashed by -63bps to 330.18% in 2020.
  • Per Business Quant, the three most recent readings for KALV's FCF Margin are 330.18% (Q2 2020), 831.26% (Q1 2020), and 202.24% (Q4 2019).